Overactive Bladder Treatment Market

Overactive Bladder Treatment Market

Overactive Bladder Treatment Market Forecasts to 2030 - Global Analysis By Type (Anticholinergics, Mirabegron, BOTOX and Other Treatments), Disease Type (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder and Other Disease Types), Distribution Channel and By Geography

4.6 (33 reviews)
4.6 (33 reviews)
Published: 2023 ID: SMRC23744

This report covers the impact of COVID-19 on this global market

Years Covered


Estimated Year Value (2023)

US $3.6 BN

Projected Year Value (2030)

US $4.8 BN

CAGR (2023 - 2030)


Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

North America

Highest Growing Market


According to Stratistics MRC, the Global Overactive Bladder Treatment Market is accounted for $3.6 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 6.2% during the forecast period. The condition known as overactive bladder (OAB) results in frequent, unexpected urinal urges that can be challenging to control. One can experience frequent urges to urinate during the day and at night, as well as inadvertent pee loss. A medical professional can identify overactive bladder by analyzing the symptoms and physically inspecting the organs close to the pelvic and rectum. Various treatments are available to treat hyperactive bladder. Changing certain behaviors, using medicine, and nerve stimulation are all possible treatments.

According to the article published in Krager Journal titled "Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation" for refractory overactive bladder, in June 2021, overactive bladder is highly prevalent worldwide and found that its overall prevalence was 11.8%.

Market Dynamics:


Rising prevalence of neurological conditions

Several drugs, including antiepileptics, antipsychotics, analgesics, and anticholinergics, are used to treat neurological illnesses. The aging population is driving market expansion, along with increased spending on the development of new drugs and devices. Additionally, government regulatory agencies and private groups are projected to launch awareness efforts to raise public knowledge of early disorder diagnosis. Additionally, effective medications will soon enter the market as a result of a robust development pipeline, which is expected to fuel market expansion.


Frequent product recalls

A large portion of the population suffers from overactive bladder, a chronic medical condition that has an adverse effect on quality of life. The expansion of the market could be hampered in the coming years by frequent recalls of OAB-treating medications. Due to production problems, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US in June 2021. Leading pharmaceutical corporations frequently recalling their products hurts the market's expansion.


Increasing R&D spending and the introduction of new treatments

Pharmaceutical and biopharmaceutical companies are now investing in cutting-edge medicines for the treatment of overactive bladders, which are anticipated to be introduced throughout the projected period. In addition, more than 30 OAB candidates are presently in clinical development pathways. These are divided into three Phase II, seven Phase III, and sixteen Phase IV projects. The market for treating overactive bladder is anticipated to grow as a result of this strong pipeline and the eventual introduction of additional medications and therapies. Samsung Medical Center is researching potential biomarkers in OAB patients, including adenosine triphosphate (ATP), prostaglandin E2 (PGE2), and nerve growth factor (NGF). Players in the OAB treatment market can anticipate benefiting from significant growth prospects as a result of such advances.


Lack of knowledge about its prevalence

One of the things preventing the market from expanding is the dearth of medications in Phase III development or the pre-registration stages. Additionally, throughout the forecast period, market expansion is hampered by the availability of complementary therapies, a lack of healthcare infrastructure in developing nations, and a shortage of qualified specialists. Recalls of products and stringent government regulations are also impeding industry expansion.

Covid-19 Impact

The COVID-19 outbreak had a beneficial effect on the expansion of the overactive bladder sector globally. The patient's bladder dysfunction was greatly exacerbated by COVID-19 association cystitis (CAC), which also caused issues unique to other organs. This had a favorable effect on the market for treatments for overactive bladder both during and after the epidemic. The COVID-19 epidemic, on the other hand, presented one of the greatest difficulties for the healthcare system. Due to the protracted lockdown in important nations like the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of production facilities. This had some impact on the production of drugs for overactive bladder.

The anticholinergics segment is expected to be the largest during the forecast period

The anticholinergics segment is estimated to have a lucrative growth, due to the primary choice of medications for treating overactive bladder syndrome is anticholinergics. Additionally, the U.S. Food and Drug Administration's quick product approvals for generic medications support the expansion of the anticholinergic market. Additionally, it has been predicted that a movement in end users' preferences of botox treatment over invasive surgery or oral drugs will increase the segment's development potential in the overactive bladder therapeutics market over the course of the projection year.

The idiopathic overactive bladder segment is expected to have the highest CAGR during the forecast period

The idiopathic overactive bladder segment is anticipated to witness the highest CAGR growth during the forecast period, due to rising rates of idiopathic overactive bladder in patients and rising demand for overactive bladder drugs for the treatment of idiopathic overactive bladder. The sector for neurogenic overactive bladder, on the other hand, is anticipated to expand at the quickest rate during the forecast period due to the rise in neurological diseases, which is predicted to increase the incidence of overactive bladder.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its robust healthcare sector. In addition, factors such as reimbursement for overactive bladder treatment, an increasing incidence of the condition with advancing age, and the presence of significant industry players in the region. Moreover, the market is set to benefit from the growing elderly population, and the substantial presence of an aging demographic in the region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, due to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Moreover, an increase in medical spending and the use of high-tech manufacturing techniques to enhance the production of drugs for treating overactive bladder with largest pharmaceutical sector and the largest supply of medicines, with easy access to a plentiful supply of raw materials for pharmaceutical product producers in this region. In addition, because of the expanding industrial infrastructure, rising disposable incomes, and established domestic company presence in the area.

Key players in the market

Some of the key players profiled in the Overactive Bladder Treatment Market include Dr. Reddy’s Laboratories Ltd, Pfizer Inc. , Cipla Ltd, Lupin, Sun Pharmaceutical Industries Ltd., Astellas Pharma Inc., AbbVie Inc., Alembic Pharmaceuticals Limited, Sumitomo Pharma Co., Ltd, Teva Pharmaceutical Industries Limited, Johnson & Johnson Services, Inc., Medtronic, Sanofi, Uro Medical, Urovant Sciences, Macleods Pharmaceuticals Ltd, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc. and Laborie

Key Developments:

In July 2022, Dr. Reddy’s Laboratories introduced fesoterodine fumarate extended-release tablets, a therapeutic generic equivalent to Pfizer’s Toviaz (fesoterodine fumarate) ER tablets in the United States for the treatment of overactive bladder.

In April 2022, Dr Reddy's launched generic Methylprednisolone Sodium Succinate for injection in US, The injection is the generic equivalent of SOLUMEDROL and has been approved by the US Food and Drug Administration (USFDA), the company said in a regulatory filing.

In May 2022, Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., presented data from the Phase 3 EMPOWUR Extension Study of GEMTESA(vibegron) 75 mg overactive bladder therapy.

Treatments Covered:
• Anticholinergics
• Mirabegron
• Neuromodulation
• Other Treatments

Disease Types Covered:
• Neurogenic Overactive Bladder
• Idiopathic Overactive Bladder
• Other Disease Types

Distribution Channels Covered:
• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers
• Other Distribution Channels

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Overactive Bladder Treatment Market, By Treatment
5.1 Introduction
5.2 Anticholinergics
5.2.1 Darifenacin
5.2.2 Fesoterodine
5.2.3 Oxybutynin
5.2.4 Solifenacin
5.2.5 Tolterodine
5.2.6 Trospium
5.2.7 Other Anticholinergics
5.3 Mirabegron
5.5 Neuromodulation
5.6 Other Treatments

6 Global Overactive Bladder Treatment Market, By Disease Type
6.1 Introduction
6.2 Neurogenic Overactive Bladder
6.2.1 Parkinson's disease
6.2.2 Strokes
6.2.3 Multiple Sclerosis
6.2.4 Spinal Cord Injuries
6.3 Idiopathic Overactive Bladder
6.4 Other Disease Types

7 Global Overactive Bladder Treatment Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Drug Stores and Retail Pharmacies
7.4 Online Providers
7.5 Other Distribution Channels

8 Global Overactive Bladder Treatment Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Dr. Reddy’s Laboratories Ltd
10.2 Pfizer Inc.
10.3 Cipla Ltd
10.4 Lupin
10.5 Sun Pharmaceutical Industries Ltd.
10.6 Astellas Pharma Inc.
10.7 AbbVie Inc.
10.8 Alembic Pharmaceuticals Limited
10.9 Sumitomo Pharma Co., Ltd
10.10 Teva Pharmaceutical Industries Limited
10.11 Johnson & Johnson Services, Inc.
10.12 Medtronic
10.13 Sanofi
10.14 Uro Medical
10.15 Urovant Sciences
10.16 Macleods Pharmaceuticals Ltd
10.17 Endo International PLC
10.18 Hisamitsu Pharmaceutical Co., Inc.
10.19 Laborie

List of Tables
1 Global Overactive Bladder Treatment Market Outlook, By Region (2021-2030) ($MN)
2 Global Overactive Bladder Treatment Market Outlook, By Type (2021-2030) ($MN)
3 Global Overactive Bladder Treatment Market Outlook, By Anticholinergics (2021-2030) ($MN)
4 Global Overactive Bladder Treatment Market Outlook, By Darifenacin (2021-2030) ($MN)
5 Global Overactive Bladder Treatment Market Outlook, By Fesoterodine (2021-2030) ($MN)
6 Global Overactive Bladder Treatment Market Outlook, By Oxybutynin (2021-2030) ($MN)
7 Global Overactive Bladder Treatment Market Outlook, By Solifenacin (2021-2030) ($MN)
8 Global Overactive Bladder Treatment Market Outlook, By Tolterodine (2021-2030) ($MN)
9 Global Overactive Bladder Treatment Market Outlook, By Trospium (2021-2030) ($MN)
10 Global Overactive Bladder Treatment Market Outlook, By Other Anticholinergics (2021-2030) ($MN)
11 Global Overactive Bladder Treatment Market Outlook, By Mirabegron (2021-2030) ($MN)
12 Global Overactive Bladder Treatment Market Outlook, By BOTOX (2021-2030) ($MN)
13 Global Overactive Bladder Treatment Market Outlook, By Neuromodulation (2021-2030) ($MN)
14 Global Overactive Bladder Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
15 Global Overactive Bladder Treatment Market Outlook, By Disease Type (2021-2030) ($MN)
16 Global Overactive Bladder Treatment Market Outlook, By Neurogenic Overactive Bladder (2021-2030) ($MN)
17 Global Overactive Bladder Treatment Market Outlook, By Parkinson's disease (2021-2030) ($MN)
18 Global Overactive Bladder Treatment Market Outlook, By Strokes (2021-2030) ($MN)
19 Global Overactive Bladder Treatment Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
20 Global Overactive Bladder Treatment Market Outlook, By Spinal Cord Injuries (2021-2030) ($MN)
21 Global Overactive Bladder Treatment Market Outlook, By Idiopathic Overactive Bladder (2021-2030) ($MN)
22 Global Overactive Bladder Treatment Market Outlook, By Other Disease Types (2021-2030) ($MN)
23 Global Overactive Bladder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
24 Global Overactive Bladder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
25 Global Overactive Bladder Treatment Market Outlook, By Drug Stores and Retail Pharmacies (2021-2030) ($MN)
26 Global Overactive Bladder Treatment Market Outlook, By Online Providers (2021-2030) ($MN)
27 Global Overactive Bladder Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

List of Figures


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.

Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.

For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.


Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.